Actionable news
All posts from Actionable news

Biotech Stocks on Investors' Radar — Synthetic Biologics, 22nd Century, Abeona Therapeutics, and Aeterna Zentaris

If you want a Stock Review on SYN, XXII, ABEO, or AEZS then come over to and sign up for your free customized report. On Monday, October 30, 2017, US markets saw broad based losses with seven out of nine sectors finishing the trading sessions in red. Major US indices were also bearish at the close of yesterday's session. The NASDAQ Composite ended the day at 6,698.96, down 0.03%; the Dow Jones Industrial Average edged 0.36% lower, to finish at 23,348.74; and the S&P 500 closed at 2,572.83, down 0.32%. This Tuesday morning, looks at the performance of these four Biotechnology stocks: Synthetic Biologics Inc. (NYSE AMER: SYN), 22nd Century Group Inc. (NYSE AMER: XXII), Abeona Therapeutics Inc. (NASDAQ: ABEO), and Aeterna Zentaris Inc. (NASDAQ: AEZS). This morning's free research reports on the aforesaid equities can be accessed upon registration on at:

Synthetic Biologics

On Monday, shares in Rockville, Maryland headquartered Synthetic Biologics Inc. recorded a trading volume of 538,244 shares. The stock ended the session 3.20% lower at $0.80. The Company's shares have gained 63.21% over the previous three months. The stock is trading above its 200-day moving average by 16.69%. Moreover, shares of Synthetic Biologics, which develops therapeutics designed to preserve the microbiome to protect and restore the health of patients in the US, have a Relative Strength Index (RSI) of 39.36. Visit us today and download your complete report on SYN for free at:

22nd Century Group

Clarence, New York headquartered 22nd Century Group Inc.'s stock closed the day 4.82% lower at $2.17 with a total trading volume of 5.27 million shares, which was above their three months average volume of 4.61 million shares. The Company's shares have advanced 14.21% in the previous three months, 65.65% over the last twelve months, and 99.08% since the start of this year. The stock is trading above its 200-day moving average by 28.15%. Additionally, shares of 22nd Century, which provides technology that allows for the level of nicotine and other nicotinic alkaloids in tobacco plants to be decreased or increased through genetic engineering and plant breeding, have an RSI of 35.78.

On October 16th, 2017, research firm Chardan Capital Markets reiterated its 'Buy' rating on the Company's stock with an increase of the target price from $3.50 a share to $11.50 a share. The complimentary research report on XXII can be accessed at:

Abeona Therapeutics

Shares in Dallas, Texas-based Abeona Therapeutics Inc. recorded a trading volume of 650,943 shares. The stock ended yesterday's trading session 0.87% higher at $17.45. The Company's shares have advanced 116.77% over the previous three months, 147.52% in the past twelve months, and 259.79% on an YTD basis. The stock is trading above its 50-day and 200-day moving average by 15.28% and 111.05%, respectively. Furthermore, shares of Abeona Therapeutics, which focuses on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases, have an RSI of 52.44.

On October 16th, 2017, research firm H.C. Wainwright reiterated its 'Buy' rating on the Company's stock with an increase of the target price from $20 a share to $30 a share. Register for free on and download the research report on ABEO at:

Aeterna Zentaris

Summerville, South Carolina headquartered Aeterna Zentaris Inc.'s stock finished Monday's session flat at $1.88 with a total trading volume of 96,865 shares. The Company's shares have advanced 9.30% over the previous three months. The stock is trading below its 50-day moving average by 6.54%. Additionally, shares of Aeterna Zentaris, which engages in developing and commercializing novel treatments in oncology, endocrinology, and women's health, have an RSI of 37.21. Get free access to your research report on AEZS at:


Daily Stock Tracker:

Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

DST has not been compensated; directly or indirectly; for producing or publishing this document.


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.


DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: (207)331-3313
Office Address: 377 Rivonia Boulevard, Rivonia, South Africa

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.